Literature DB >> 22178074

SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production.

Siti Nur Aisyah Jauharoh1, Jun Saegusa, Takeshi Sugimoto, Bambang Ardianto, Shimpei Kasagi, Daisuke Sugiyama, Chiyo Kurimoto, Osamu Tokuno, Yuji Nakamachi, Shunichi Kumagai, Seiji Kawano.   

Abstract

SS-A/Ro52 (Ro52), an autoantigen in systemic autoimmune diseases such as systemic lupus erythematosus and Sjögren's syndrome, has E3 ligase activity to ubiquitinate proteins that protect against viral infection. To investigate Ro52's role during stress, we transiently knocked it down in HeLa cells by siRo52 transfection. We found that Ro52(low) HeLa cells were significantly more resistant to apoptosis than wild-type HeLa cells when stimulated by H(2)O(2)- or diamide-induced oxidative stress, IFN-α, IFN-γ and anti-Fas antibody, etoposide, or γ-irradiation. Furthermore, Ro52-mediated apoptosis was not influenced by p53 protein level in HeLa cells. Depleting Ro52 in HeLa cells caused Bcl-2, but not other Bcl-2 family molecules, to be upregulated. Taken together, our data showed that Ro52 is a universal proapoptotic molecule, and that its proapoptotic effect does not depend on p53, but is exerted through negative regulation of the anti-apoptotic protein Bcl-2. These findings shed light on a new physiological role for Ro52 that is important to intracellular immunity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178074     DOI: 10.1016/j.bbrc.2011.12.010

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

Authors:  Adrianos Nezos; Fotini Gravani; Anna Tassidou; Efstathia K Kapsogeorgou; Michael Voulgarelis; Michael Koutsilieris; Mary K Crow; Clio P Mavragani
Journal:  J Autoimmun       Date:  2015-07-14       Impact factor: 7.094

Review 2.  Update on Pathogenesis of Sjogren's Syndrome.

Authors:  Pulukool Sandhya; Biji Theyilamannil Kurien; Debashish Danda; Robert Hal Scofield
Journal:  Curr Rheumatol Rev       Date:  2017

3.  Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers.

Authors:  Qianshan Ding; Du He; Ke He; Qian Zhang; Meng Tang; Jinfen Dai; Hanlin Lv; Xiaochen Wang; Guoan Xiang; Honggang Yu
Journal:  Tumour Biol       Date:  2015-06-09

4.  The Sjögren's syndrome-associated autoantigen Ro52/TRIM21 modulates follicular B cell homeostasis and immunoglobulin production.

Authors:  S Brauner; M Ivanchenko; G E Thorlacius; A Ambrosi; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2018-10-16       Impact factor: 4.330

Review 5.  A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity.

Authors:  Adrian Y S Lee
Journal:  Rheumatol Int       Date:  2017-04-17       Impact factor: 2.631

6.  UMAOH Calcium Phosphate Coatings Designed for Drug Delivery: Vancomycin, 5-Fluorouracil, Interferon α-2b Case.

Authors:  Konstantin A Prosolov; Ekaterina G Komarova; Ekaterina A Kazantseva; Aleksandr S Lozhkomoev; Sergei O Kazantsev; Olga V Bakina; Marina V Mishina; Anastasia P Zima; Sergei V Krivoshchekov; Igor A Khlusov; Yurii P Sharkeev
Journal:  Materials (Basel)       Date:  2022-07-01       Impact factor: 3.748

7.  TRIM21, a negative modulator of LFG in breast carcinoma MDA-MB-231 cells in vitro.

Authors:  Judith Müller; Viktor Maurer; Kerstin Reimers; Peter M Vogt; Vesna Bucan
Journal:  Int J Oncol       Date:  2015-09-16       Impact factor: 5.650

8.  Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons.

Authors:  He Li; Tove Ragna Reksten; John A Ice; Jennifer A Kelly; Indra Adrianto; Astrid Rasmussen; Shaofeng Wang; Bo He; Kiely M Grundahl; Stuart B Glenn; Corinne Miceli-Richard; Simon Bowman; Sue Lester; Per Eriksson; Maija-Leena Eloranta; Johan G Brun; Lasse G Gøransson; Erna Harboe; Joel M Guthridge; Kenneth M Kaufman; Marika Kvarnström; Deborah S Cunninghame Graham; Ketan Patel; Adam J Adler; A Darise Farris; Michael T Brennan; James Chodosh; Rajaram Gopalakrishnan; Michael H Weisman; Swamy Venuturupalli; Daniel J Wallace; Kimberly S Hefner; Glen D Houston; Andrew J W Huang; Pamela J Hughes; David M Lewis; Lida Radfar; Evan S Vista; Contessa E Edgar; Michael D Rohrer; Donald U Stone; Timothy J Vyse; John B Harley; Patrick M Gaffney; Judith A James; Sean Turner; Ilias Alevizos; Juan-Manuel Anaya; Nelson L Rhodus; Barbara M Segal; Courtney G Montgomery; R Hal Scofield; Susan Kovats; Xavier Mariette; Lars Rönnblom; Torsten Witte; Maureen Rischmueller; Marie Wahren-Herlenius; Roald Omdal; Roland Jonsson; Wan-Fai Ng; Gunnel Nordmark; Christopher J Lessard; Kathy L Sivils
Journal:  PLoS Genet       Date:  2017-06-22       Impact factor: 5.917

9.  TWEAK/Fn14 Activation Participates in Ro52-Mediated Photosensitization in Cutaneous Lupus Erythematosus.

Authors:  Yale Liu; Meifeng Xu; Xiaoyun Min; Kunyi Wu; Ting Zhang; Ke Li; Shengxiang Xiao; Yumin Xia
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

10.  TRIM21 is a novel regulator of Par-4 in colon and pancreatic cancer cells.

Authors:  Jeffrey Q Nguyen; Rosalyn B Irby
Journal:  Cancer Biol Ther       Date:  2016-11-10       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.